HealthExec June 6, 2024
Chad Van Alstin

The U.S. Food and Drug Administration (FDA) has agreed in a unanimous vote to recommend an update of the formula for the COVID-19 vaccine in time for the annual booster campaign this fall.

The new formula is aimed at curbing the JN.1 variant of the virus, which the FDA’s committee of independent advisors said is causing the majority of infections. Officially, the decision by the FDA is a request to drug manufacturers to change course—that is, if the recommendation is approved.

The committee’s recommendation now moves up the ladder at the FDA for approval. What’s new in this scenario is the booster formula would be monovalent, to counter the JN.1 variant specifically. Previous iterations of COVID-19 boosters have...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
STAT+: Trump’s FDA director pick has a history of criticizing the agency. Here are seven examples
Trump names nominees to lead CDC, FDA, and his pick for surgeon general
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
New FDA Panel Weighs In on Regulating Generative AI in Healthcare
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA

Share This Article